<DOC>
	<DOCNO>NCT02079519</DOCNO>
	<brief_summary>This study evaluate efficacy safety Avastin ( bevacizumab , 5 mg/kg intravenously every 2 week ) patient multiple myeloma , relapsed/refractory least 2 line prior therapy .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , 1975 year age Multiple myeloma . Progressive disease least 2 line prior therapy . Nonsecretory myeloma . History malignancy , squamous cell cancer , basal cell cancer , cancer situ cervix within last 5 year . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start . Clinically significant cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>